Inovio Pharmaceuticals INO makes DNA medicines to potentially treat and prevent diseases associated with human papillomavirus (HPV), cancer and infectious ailments, using its proprietary optimized ...
Retrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial ...
Inovio Pharmaceuticals (NASDAQ:INO) had a slight setback with its timeline on when it could actually file its Biologics License Application [BLA] of INO-3107 for the treatment of patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback